$RGBP "dCellVax is one of the programs we are developing to activate the immune system in order to allow the body to kill cancer. Immune modulation, both inhibitory and stimulatory, is unlocking many novel ways to have the human body heal itself. dCellVax is only one of our immune modulatory products that we expect to bring to market in the future. The data package we sent to the FDA is an important step in this process," said Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.